1. Germany Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Biofrontera AG

Biofrontera AG

3.00
EUR
-0.06
(-1.96%)
-0.56EPS
Nov 19Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.28
2.31
3.32
4.03
6.18
9.45
13.68
11.25
10.44
9.4
10.61
2
2.17
1.86
Basic EPS, GAAP
-5.9
-7.99
-8.99
-6.96
-8.27
-3.97
-3.22
-4.83
13.69
-16.14
-0.12
-0.72
-0.65
0.43
Free Cash Flow per Basic Share
-5.53
-6.03
-7.89
-7.06
-6.94
-6.24
-15.21
-1.34
10.81
-1.78
-0.93
-0.45
-0.73
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-4.16
-0.02
-3.06
7.82
1.64
7.17
4.34
3.02
20.34
6.69
6.58
3.1
2.45
2.81
Tangible Book Value per Share
-7.08
-1.9
-4.27
7.21
1.33
7.01
-5.62
-4.22
19.94
6.3
6.2
2.94
2.36
2.81
Basic Weighted Avg Shares
1
1
1
2
2
2
2
3
3
3
3
6
6
6
Sales/Revenue/Turnover
3
3
4
6
12
21
31
30
29
26
32
12
13
11
Operating Margin (%)
-229.17
-311.64
-247.25
-192.15
-115.88
-87.54
-74.77
-25.08
-122.76
6.18
14.83
-13.03
-7.77
-20.71
Depreciation Expense
1
1
1
1
1
1
3
5
3
1
1
1
1
- -
Net Income, GAAP
-8
-11
-11
-11
-16
-9
-7
-13
38
-44
- -
-4
-4
3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
6.72
- -
- -
- -
- -
- -
Profit Margin (%)
-259
-346.33
-270.73
-172.58
-133.9
-42.06
-23.53
-42.92
131.13
-171.6
-1.14
-35.71
-30.06
22.83
Working Capital
4
8
4
18
14
20
11
18
-3
7
8
6
8
9
LT Debt
12
11
11
4
12
13
22
23
1
1
1
- -
- -
1
Total Equity
-5
- -
-5
16
3
16
10
7
57
20
20
19
15
17
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-72.98
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
101.64
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-167.53
-89.96
-55.93
-150.29
116.5
-113.59
-1.83
-22.4
-23.49
14.5

Capital Structure

EUR

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
- -
- -
- -

Working Capital

EUR

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
15
14
13
Cash, Cash Equivalents & STI
4
4
6
Accounts Receivable, Net
2
6
4
Inventories
4
4
4
Total Current Liabilities
5
6
4
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
39.64%
117.15%
-20.95%
Free Cash Flow
-92.41%
-204.38%
61.91%
Net Income, GAAP
42.56%
72.8%
-8.85%
Sales/Revenue/Turnover
22.06%
-8.88%
8.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4
3
4
11
12
2025
3
- -
4
1
13
2026
4
- -
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.89
-0.43
-0.15
0.32
-0.72
2025
0.11
- -
-0.06
0.02
-0.65
2026
0.36
- -
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hermann Lübbert
Full Time Employees
82
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Hemmelrather Weg 201 Leverkusen NW Germany 51377
IPO Date
Oct 30, 2006
Website
biofrontera.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Biofrontera AG is a Germany-based biopharmaceutical company focused on the development, production, and distribution of dermatological therapeutics and related medical cosmetics. The company specializes in photodynamic therapy (PDT) for skin conditions, including actinic keratoses and certain skin cancers, and markets associated devices and topical formulations; its flagship offerings include Ameluz, a topical prescription drug used in PDT, and the BF-RhodoLED lamp system used to activate Ameluz, along with Belixos, a herbal-based dermatological cream for inflammatory and itchy skin conditions. Biofrontera operates across Europe, the United States, and other international markets, leveraging a multi-channel commercial framework to reach dermatology clinics, hospitals, and specialty distributors. The company was founded in 1991 and is headquartered in Leverkusen, Germany. In addition to its core prescription products, Biofrontera provides development and collaboration programs for dermatology products, and pursues ongoing expansions in Europe and North America through strategic partnerships and regional market access initiatives. Subsidiaries and affiliated entities support regional sales, regulatory compliance, and product distribution, with corporate governance anchored in its listed status on European exchanges under the ticker B8FK.DE. Latest corporate developments include strategic partnerships to broaden market presence in key territories, ongoing commercialization of Ameluz and BF-RhodoLED globally, and operational restructurings to optimize European cost structure and independence from Biofrontera Inc. to enhance profitability and growth in core markets. Biofrontera remains focused on acquiring regulatory approvals, advancing pipeline candidates related to dermatology, and expanding patient access to photodynamic therapy platforms.